Evidence map›Paper›PMID 42712076›Full record

ArticleDiabetes, obesity & metabolism2026

A Biweekly GLP-1R Agonist Designed With Drug-Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability.

Wei Ding, Qing Liu, Qiong Luo, Xiaojun Yao, Xingxing Fan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wei DingSchool of Pharmacy, Faculty of Medicine & Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Macau, China.ORCID https://orcid.org/0009-0008-7483-5584
Qing LiuSchool of Biomedical Engineering, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.ORCID https://orcid.org/0000-0002-0773-3843
Qiong LuoDepartment of Basic Medical Sciences, Changsha Medical University, Changsha, Hunan, China.ORCID https://orcid.org/0009-0008-6130-2033
Xiaojun YaoFaculty of Applied Sciences, Macao Polytechnic University, Macau, China.ORCID https://orcid.org/0000-0001-9958-8438
Xingxing FanSchool of Pharmacy, Faculty of Medicine & Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau University of Science and Technology, Macau, China.ORCID https://orcid.org/0000-0002-7751-7193

Funding

Nanjing Chi Heal Biomedicine Technology Co., Ltd.Nanjing Major Science and Technology Special Project (Life and Health) 202305006Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd.
6 · The paper itself

Abstract

aimTo develop a next-generation, longer-acting, more-clinical-benefits agonist to achieve sustained efficacy with improved tolerability.

methodsCT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays. Pharmacokinetics were profiled in SD rats; metabolic efficacy was evaluated in B6/ob and DIO mice (CT130 biweekly vs semaglutide weekly). Receptor trafficking dynamics and cholesterol regulation were dissected mechanistically. Toxicology was assessed in rodents and a primate pilot study.

resultsCT130 retained high GLP‑1R affinity (EC

conclusionsCT130 is a safe, once biweekly preclinical candidate that incorporates drug free intervals to allow GLP 1R restore. It delivers robust, lasting metabolic benefits with improved gastrointestinal tolerability, and offering a template for next generation long acting GLP 1R agonists.

Indexed as

Gastrointestinal TractGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsObesityAnimalsDrug Administration ScheduleGlucagon-Like Peptide-1 ReceptorHomeostasisHumansMacaca fascicularisMaleMiceMice, Inbred C57BLRatsRats, Sprague-DawleyGlp1r protein, ratGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsSemaglutidecholesterol metabolismdrug‐free intervalenterohepatic axisgastrointestinal tolerabilityGLP‐1 receptor agonistGLP‐1R homeostasisobesityPCSK9semaglutideSREBP‐2

Identifiers

PMID42712076
PMCPMC13731067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.